anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study design was a single group (n=26) with repeated testing (3 times) pre- and post-treatment. All participants received the same treatment protocol (described in detail in Appendix A and in Minkina et al. (under review)). In order to control for improvement in language function related to passage of time, and for the effect of repeated exposure to outcome measures, individuals were randomly assigned to one of two conditions: delayed treatment or immediate treatment (Figure 2). Participants who were randomized to the delayed group received repeated testing three times before and three times after a six-week delay. During the delay phase they were permitted to participate in usual speech-language care (e.g., conversation groups and individual therapy).

Standardized assessments and outcome measures (described in detail below) were administered prior to the start of treatment (for both immediate and delayed groups), at the end of the delay phase (delayed group only), immediately after treatment termination, and at three months post-treatment.
PURPOSE: A composition containing mixture herb extract is provided to reduce blood glucose, cholesterol, LDL-cholesterol, and triglyceride level. CONSTITUTION: A pharmaceutical composition for preventing and treating hyperlipidemia and diabetic hyperlipidemia contains mixture herb extract of Mori Cortex Radicis, Licii Radicis Cortex, and Dioscoreae Rhisoma as an active ingredient. The composition additionally contains Lonicerae Flos. The mixture herb extract is isolated using water, low alcohol of C1-C4, or mixture solvent thereof. A health food for preventing and treating hyperlipidemia and diabetic hyperlipidemia contains mixture herb extract of Mori Cortex Radicis, Licii Radicis Cortex, and Dioscoreae Rhisoma as an active ingredient. The health food is used in the form of powder, granule, capsule, or beverage.
Multisystemic inflammatory syndrome in adults is a hyperinflammatory condition following (within 4-12 weeks) SARS-CoV-2 infection. Here, the dysregulation of the immune system leads to a multiorgan involvement often affecting the heart. Cardiac involvement in multisystemic inflammatory syndrome in adults has been described mainly in young men without other comorbidities and may present with different clinical scenarios, including acute heart failure, life-threatening arrhythmias, pericarditis, and myocarditis, with a nonnegligible risk of mortality (up to 7% of all cases). The heterogeneity of its clinical features and the absence of a clear case definition make the differential diagnosis with other postinfectious (eg, infective myocarditis) and hyperinflammatory diseases (eg, adult Still disease and macrophage activation syndrome) challenging. Moreover, the evidence on the efficacy of specific treatments targeting the hyperinflammatory response underlying this clinical condition (eg, glucocorticoids, immunoglobulins, and other immunomodulatory agents) is sparse and not supported by randomized clinical trials. In this review article, we aim to provide an overview of the clinical features and the diagnostic workup of multisystemic inflammatory syndrome in adults with cardiac involvement, highlighting the possible pathogenetic mechanisms and the therapeutic management, along with remaining knowledge gaps in this field.
ADVAIR DISKUS is indicated for the treatment of asthma in patients aged 4 years and older. 

Long-acting beta2-adrenergic agonists (LABAs), such as salmeterol, one of the active ingredients in ADVAIR DISKUS, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABAs increase the risk of asthma-related hospitalization in pediatric and adolescent patients [see Warnings and Precautions (5.1)]. Therefore, when treating patients with asthma, physicians should only prescribe ADVAIR DISKUS for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid, or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue ADVAIR DISKUS) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use ADVAIR DISKUS for patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids.

Important Limitation of Use: ADVAIR DISKUS is NOT indicated for the relief of acute bronchospasm.
Patients will have their white blood cells removed and grown in culture under conditions to make dendritic cells. Dendritic cells are a small group of cells that belong to the white blood cell population. These cells are responsible for letting the immune system know that something foreign, like bacteria or a tumor, is in the body. Dendritic cells help the body ward off disease by alerting the immune system. In previous clinical trials, brain tumor cells called astrocytoma tumor cells and glioblastoma tumor cells were taken from the tumor that was removed during surgery. The brain tumor cells were then placed into a solution in the laboratory that made them grow. Certain parts of the brain tumor's proteins (peptides) were removed from the growing tumor cells and mixed together with the dendritic cells in the blood taken from a vein. This combination of dendritic cells and brain tumor peptides were injected into the patient's skin, like a vaccination. This process is similar to that used in vaccinations. The patients were given three and four injections of dendritic cells mixed with the tumor peptides over the course of a twenty-eight day period.

In this study, the proteins that are manufactured and known to be associated with brain cancers will be mixed with the dendritic cells obtained during leukopheresis (a procedure in which the dendritic cells are separated from the patients' blood). They will then undergo three vaccinations along with follow up clinic visits (which include evaluations and laboratory tests) to check their status.

The investigators learned that it was possible to generate an immune response in a subset of patients with malignant glioma. In addition, these cells were able to reach the brain and kill brain tumor cells. The survival of patients in this study was prolonged when compared to historical controls. Based on clinical data in subjects with brain tumors, the investigators believe that peripheral injection of dendritic cells will generate a more potent immune response for patients with brain stem gliomas and/or glioblastomas. The investigators hope to determine whether this therapy will translate into a longer survival and better quality of life in these patients in whom survival is measured in months. Through this study the investigators hope to learn more about the role of the body's immune response against cancer and about the use of dendritic cells for immunotherapy. This information may prove useful in the therapy of patients with glioblastoma and/or brainstem gliomas.
Buprenorphine is a μ-opioid partial agonist and kappa-opioid antagonist that is used to treat moderate to severe pain and opioid dependence. The intramuscular administered opioid agonist which will be used to modulate reward learning signals to understand placebo effects in patients with depression. In the buprenorphine condition, participants will receive one IM injection of 0.3mg/1ML buprenorphine hydrochloride (Buprenex®. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc.; 2006) (onset of action: ≥15 minutes; peak effect: \~1 hour; duration: \~6 hours) and an oral placebo tablet.
A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The Ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast.
Bioparyl is obtainable by a disclosed extraction hydrolysis and purification procedure applied to golden autumn leaves of the Gingko biloba tree. Bioparyl plays an important role in the regulation of the activity of certain enzymes, particularly ribonucleases (RNases), implicated in the fundamental mechanism of gene expression. It is low in or free from toxic or side effects in healthy animals, and can be used to ameliorate several pathogenic conditions. Bioparyl is effective in preventing or reversing fibrosis in various tissues, including the lungs and skin, engendered by radiation or chemotherapy. It reduces abnormally high concentrations of gamma-globulins and immuno-globulins found in certain inflammatory or auto-immune diseases, including Acquired Immune Deficiency Syndrome disease (AIDS). In patients with leukemia or solid cancers, Bioparyl normalizes the activity of ribonucleases.
This is benzenenonanol ether foam agent and method for making same, and its characteristic is: it is made from benzenenonanol and other raw materials. Its manufacturing technique is: dissolve benzenenonanol in water, and unfreeze dodesyl sodium sulfate, doctacosanol and wool alcohol on water bath; mix the two liquids and agitate homogeneous, then add distilled water to the total amount and agitate homogeneous, then pour it into pressure net foam latex generator, which can generate foam when pressing its foam latex pump, or pour it into voltage-withstand vessel and add propellant, press valve can generate foam through propellant. Using pressure net foam latex generator, generating foam by pressing a foam latex pump can save cost, reduce environmental pollution caused by propellant, reduce pressurized vessel easy-burst and make it safer. The foam agent can make medicine distribute even and broad in vagina cavity or on skin surface, make the medicine filter into vagina mucosa crink-wall. It has characteristics of therapeutic effect volatilization plenty and quick, therapeutic effect good, health, safety and convenient. It is a fine medicine for killing spermium.
The invention relates to a drug with magnetic microspheres, and a use thereof, and belongs to the technical field of biological agent. According to the present invention, a target identification material and/or a target drug is conjugated to the magnetic microspheres to form a conjugate of the magnetic microspheres and the target identification material and/or the target drug, wherein the target identification material comprises at least one selected from antigen, antibody and nucleic acid. The target drug is a conjugate prepared through conjugating the target identification material to the drug. The drug comprises at least one selected from a chemically-synthesized drug, a naturally extracted drug and a biological drug. With the present invention, the hematogenic immunity and the circle target treatment apparatus are combined, such that harmful antigenic substances in the blood can be removed or killed outside the patient body, wherein the clearance rate can reach more than 90%; the problem of immunological rejection generating in the patient body due to the target drug or the target identification material in the prior art is solved. The present invention further provides the new use of the conjugate in preparing the drug for clearing or killing the harmful antigenic substances in the blood, wherein the conjugate is prepared through conjugating the magnetic microspheres to the target identification material and/or the target drug.
FIELD: medicine. SUBSTANCE: this new method of treating persisting respiratory virus diseases prescribes daily intranasaly administering exogenous leukocytic interferon in dose of 0.1 to 0.2 once a day in the morning during 2 to 2.5 months and at the same time perorally administering antioxidant coretinoids in doses depending on age three times a day during 2 to 2.5 months and then perorally administering vegetational-origin exogenous interferon generation stimulators, 1.5 to 2.0 months after starting administration of exogenous interferon, three times a day during 2.0 to 2.5 months in doses depending upon specific age. Clinical effectiveness of using this method of treatment is 2.5 to 3.0 times as great as that yielded by basic curing methods. Remission shows itself in 88 % of patients. Rate of occurrence of acute respiratory diseases has dropped to about 3,57 ± 0,19. Longevity of remission has certainly extended to about 97,83 ± 0,18 days. EFFECT: excellent method of treating acute respiratory diseases. 2 tbl
BACKGROUND: Although back pain may be present in subjects with adolescent idiopathic scoliosis (AIS), its natural history is unknown. Therefore, this study evaluated the incidence of back pain in scoliotic adolescents longitudinally.
METHODS: This retrospective analysis examined prospectively collected pain subscale data of the Scoliosis Research Society questionnaire between the initial presentation and up to 3 years of follow-up. Consecutive subjects with AIS aged 10-18 at baseline managed by observation within the study period were included. Study subjects with at least one time point of follow-up data were considered. Alternatively, a group with physiotherapy-treated was also included for comparison.
RESULTS: We enrolled 428 subjects under observation. The incidence of back pain among study subjects was 14.7%, 18.8%, and 19.0% for the first year, second year, and third year of follow-up, respectively. Most experienced mild pain (1 out of 5 points) throughout the study. Neither incidence nor intensity of pain significantly differed between subjects under observation and received physiotherapy. Additionally, study subjects with a new onset of back pain had poorer function, self-image, and mental health scores than those without pain.
CONCLUSION: We investigated the incidence of back pain longitudinally in subjects suffering from AIS. Further validation of the current results is warranted.
The present invention relates to a treatment status information providing system, which comprises a status board and a plurality of remote controls. Each of the plurality of remote controls includes two or more buttons and a transmitting unit which generates and transmits an operation signal according to an input of the button. The status board includes a receiving unit for receiving the operation signal, a display unit for displaying a treatment status, and a control unit for controlling the display unit according to the operation signal. The display unit includes a plurality of section units corresponding to each of the plurality of remote controls. Each of the plurality of section units includes a plurality of lamps, timers, and time display units respectively corresponding to the buttons. The operation signal includes information capable of identifying the remote control and the button. The control unit operates the lamp of the section unit corresponding to the received operation signal. The timer starts a timer operation corresponding to the operated lamp, and the time display unit displays a remaining time of the timer.
Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.
<P>PROBLEM TO BE SOLVED: To provide a propolis extract exhibiting hypotensive actions on hypertension based on inhibitory actions on angiotensin converting enzymes (ACE) and inhibitory actions on phosphodiesterases (PDE) and to provide a method for producing the same and the hypotensive agent comprising the same.  <P>SOLUTION: The propolis extract comprises at least one kind selected from phenolic organic acids and caffeoylquinic acids. The content of the phenolic organic acids is ≥3 wt.% and the content of the caffeoylquinic acids is ≥5 wt.%. The method for producing the propolis extract comprises mixing a propolis raw material with a hydrous alcohol containing 10-40 vol.% of an alcohol based on water and extracting at least one kind selected from the phenolic organic acids and caffeoylquinic acids. Furthermore, the hypotensive agent comprises the propolis extract as an active ingredient.  <P>COPYRIGHT: (C)2004,JPO
A method of acquiring medical image data of a first subject by a user is provided. The method includes providing a mobile wireless-communication optical-imaging device that includes an optical imaging component, an input component, a wireless two-way communication component, a memory and a program. The program includes authenticating the user and the program includes a request for subject identifying information. The method further includes providing user authenticating data and wirelessly transmitting the user authenticating data. The method further includes the user capturing first medical image data related to a first subject with the mobile device. The optical imaging component of the mobile wireless-communication optical-imaging device is operated by the user to capture the first medical image data. The first subject is one of a plurality of different subjects, each of whom has a distinct subject medical record on a server and for each of whom medical image data is stored in the distinct subject medical record. The method further includes storing the first medical image data in the memory. The method further includes providing first subject identifying information that uniquely identifies a first subject medical record on the mobile device in response to a program request, and wirelessly transmitting the first medical image data together with the first subject identifying information to a second device for storage in the first subject medical record on the server.
<P>PROBLEM TO BE SOLVED: To provide a method for producing theophylline-containing granulated powder, by which the highly integrated granulated powder having a narrow particle size distribution width can be obtained, although water-insoluble ethylcellulose and slightly water-soluble theophylline are dispersed in an aqueous solvent and then spray-granulated, and to provide the theophylline-containing granulated powder obtained by this method.  <P>SOLUTION: The theophylline-containing granulated powder is obtained by spray-drying and granulating a dispersion comprising the theophylline, the ethylcellulose, and the aqueous solvent comprising water and a water-soluble organic solvent. The theophylline-containing granulated powder does substantially not contain a higher fatty acid glycerol ester. The ratio of the water to the water-soluble organic solvent may be about 100 pts. wt. to about 0.1 to 60 pts. wt. When the concentration of the solid content in the dispersion is enhanced to about 20 to 50 wt. %, or when the dispersion is heated (for example, to about 35 to 70°C) and then sprayed, the bulk density of the granulated powder can be enhanced. Heat input temperature in the spray-drying process may be about 150 to 260°C.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Weight and skin-fold measurements were made at five-day intervals during a 47-day expedition by six men and three women from the edge of the sea ice to the South Pole. From these, together with detailed manual records of the nutrition for individual participants, the average daily energy expenditure was determined before and after a resupply at approximately mid-point of the expedition. For all participants body weight fell during the expedition with the overall loss being much smaller for the three female participants (-4.0, -4.0, -4.4kg) than for the male participants, (mean±sd) -8.6±2.0kg. Fat weight fell approximately linearly during the expedition with a total loss of (-4.1, -6.5 and -2.5kg) for the three female participants and -6.8±1.7kg for the male participants. Individual fat-free weight changed by a smaller amount overall: (0.13, 2.5 and -1.8kg) for the three female participants; -1.8±2.0kg for the male participants who, with one exception, lost fat-free tissue All participants showed a substantial variation in fat-free tissue weight during the expedition. Analysis of the daily energy expenditure showed adequate nutrition but the intake fell for the second part of the expedition although the reasons for this are unclear, but adaptation to the cold, altitude and workload are possible explanations. The validity of this time-averaged measurement for individual participants was determined from analysing moments about the mean of time-series actigraphy data from wrist worn devices. The mean and autocorrelation function of the actigraphy data across subjects were analysed to determine whether measures could be compared between participants. The first, second and third moment about the mean of the day-to-day activity was found to be time-invariant for individual subjects (χ2, p>0.05) and the normalized mean and autocorrelation measured over a day for each participant indistinguishable from the mean of the group (χ2, p>0.05) allowing both longitudinal and cross-sectional analysis.
The invention discloses yellow sweat treating potion and in particular relates to a method for preparing the yellow sweat treating potion, medical cakes and powder. The yellow sweat treating potion to be taken orally comprises the following eleven main components in percentage by weight: 25% of artemisia capillaries, 10% of Polygonum tinctorium Ait, 5% of cassia twig, 7% of red paeony root, 7% of white paeony root, 20% of astragalus root, 5% of cape jasmine fruit, 4% of rhubarb, 8% of atractylodes lancea, 4% of radix stephaniae tetrandrae and 5% of liquorice root, wherein the eleven Chinese medicaments are ground into ultrafine powder and prepared into oral liquid. The medical cakes are prepared from Chinese gall powder which is mixed with warm water and prepared into copper coin sized medical cakes or is prepared from cucuma powder and oyster shell powder which are uniformly mixed in a ratio of 4:1 and then are uniformly mixed with rice soup to obtain copper coin sized medical cakes. The powder is prepared from oyster, largehead atractylodes rhizome, wheat bran, ephedra, Chinese lovage, glutinous rice, divaricate saposhnikovia root and dahurian angelica root which are same in parts and are ground into fine powder and packed with silk for later use. The yellow sweat treating potion is taken orally for three times a day after meals and 10-20ml for each time. A Chinese gall powder cake is applied to the navel before a patient goes to bed, and the cucuma powder and oyster shell powder cakes are applied to the left nipple acupoint and the right nipple acupoint and are replaced once a day. The medical powder which is prepared by grinding the oyster, the largehead atractylodes rhizome, the wheat bran, the ephedra, the Chinese lovage, the glutinous rice, the divaricate saposhnikovia root and the dahurian angelica root is applied to the whole body.
This study is an open-label, multicenter, PCR response adaptive clinical study design, with intensification of treatment (addition of adefovir to telbivudine treatment) depending on HBV DNA level at week 24. All patients commence with Telbivudine 600mg daily. At week 24 they will be divided into 2 Groups according to virological response. Patients with PCR detectable HBV DNA will add on ADV(Group I). Patients with PCR undetectable HBV DNA(Group II)will continue telbivudine monotherapy. ADV will not be added on unless viral breakthrough occurs.
Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.